<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672490</url>
  </required_header>
  <id_info>
    <org_study_id>D1443L00023</org_study_id>
    <nct_id>NCT00672490</nct_id>
  </id_info>
  <brief_title>Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder</brief_title>
  <acronym>MANIA</acronym>
  <official_title>An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct
      therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
      Patients with a documented clinical diagnosis of bipolar mania according to DSM-IV criteria
      (296.4X Bipolar I Disorder, Most Recent Episode Manic; 296.0X Bipolar I Disorder, Single
      Manic Episode) are required to have a YMRS total score of ≥20 at enrolment and randomisation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinical Global Impressions for Bipolar Disorder Severity of Illness (CGI-BP-S) Score to Each Assessment (Day 28)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score to Each Assessment (Day 28)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Each Assessment(Day 28)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms. The MADRS total score is the sum of all 10 individual-item scores and ranges from 0 to 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Young Mania Rating Scale (YMRS) Item 4 Score to Each Assessment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Number of Patients With Clinically Response)</measure>
    <time_frame>From Baseline to 4 weeks</time_frame>
    <description>The number of patients with clinically response (defined as ≥50% reduction in the YMRS total score from baseline to Day 28) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission Rate (Number of Patients With Clinically Significant Remission)</measure>
    <time_frame>From Baseline to 4 weeks</time_frame>
    <description>The number of patients with clinically significant remission (defined as YMRS total score ≤12) at Day 28 was calculated.
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania. Total score ≤12 indicates remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment of Agitation (Change From Baseline in the PANSS Activation Subscale Score to Day 28)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment of Aggression Risk (Change From Baseline in the PANSS Supplement Aggression Risk Subscale Score to Day 28)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>The PANSS Supplemental Aggression Risk subscale score is the sum of 3 standard PANSS items - Excitement, Hostility and Depression - and 3 supplemental PANSS items related to anger - Anger, Difficulty in Delaying Gratification and Affective Lability and ranges from 6 to 42, where 6 is the &quot;best&quot; and 42 the &quot;worst&quot; score for the combined scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Acute Mania in Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine Fumarate - tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine Fumarate - tablets and Lithium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine Fumarate</intervention_name>
    <description>Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.
Tablets</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent before initiation of any study related
             procedures. Patients who are deemed incapable of providing informed consent maybe
             enrolled if written informed consent has been obtained from the patient's Legally
             Authorized Representative.

          -  Documented clinical diagnosis meeting the DSM-IV criteria for any of the following:

          -  296.4X Bipolar I Disorder, Most Recent Episode Manic

          -  296.0X Bipolar I Disorder, Single Manic Episode

          -  Have a YMRS score of at least 20 and a score of at least 4 on 2 of the following 4
             YMRS items both at enrolment and at randomisation: Irritability, Speech, Content, and
             Disruptive/Aggressive Behaviour.

          -  Female patients of childbearing potential must have a negative urine pregnancy test at
             enrolment and be willing to use a reliable method of birth control, i.e., barrier
             method, oral contraceptive, implant, dermal contraception, long-term injectable
             contraceptive, intrauterine device, or tubal ligation, during the study.

          -  Be able to understand and comply with the requirements of the study, as judged by the
             investigator.

        Exclusion Criteria:

          -  Manic episode judged to be either:

          -  the direct physiological consequence of a treatment or medical condition other than
             Bipolar disorder.

          -  the direct physiological effect of a substance of abuse; intoxication with
             hallucinogens, inhalants, opioids, or phencyclidine and related substances.

          -  the direct physiological effect of psychostimulant or antidepressant medication.

          -  Evidence of clinically severe or active disease, or a clinical finding that is
             unstable or that, in the opinion of the investigator, would be negatively affected by
             the study medication or that would affect the study medication.

          -  History of seizure disorder, except febrile convulsions.

          -  Hospitalization period of 3 weeks or longer immediately prior to randomization for the
             index manic episode.

          -  Known history of intolerance or hypersensitivity to quetiapine or lithium, or to any
             other component in the tablets/capsules.

          -  Known lack of response to quetiapine or lithium, as judged by the investigator.

          -  Use of antipsychotic medication or mood stabilizer other than quetiapine and lithium
             at the day of randomisation (to be tapered to discontinuation between the enrolment
             visit and randomisation).

          -  Administration of a depot antipsychotic injection within 1 dosing interval (for the
             depot) before randomisation.

          -  Use of clozapine within 28 days prior to randomisation.

          -  Use of antidepressants during the enrolment period or within a period of 5 half-lives
             of the drug(s) prior to randomisation.

          -  Continuous daily use of benzodiazepines in excess of 4 mg per day of lorazepam, or the
             equivalent, during 28 days prior to randomisation.

          -  Use of drugs that induce or inhibit the hepatic metabolizing cytochrome 3A4 enzymes
             within 14 days before randomisation.

          -  Receipt of electroconvulsive therapy (ECT) within 28 days prior to randomisation.

          -  Clinically significant deviation from the reference range in clinical laboratory test
             results at enrolment, as judged by the investigator.

          -  An absolute neutrophil count (ANC) of &lt;1.5X109/L.

          -  Treatment with quetiapine with a dosage of at least 50 mg/day at enrolment (Visit 1)

          -  Liver function test AST or ALT 2 times as the upper normal limit.

          -  A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit
             of the normal range of the laboratory used for sample analysis at enrolment, whether
             or not the subject is being treated for hypothyroidism.

          -  Known diagnosis of Diabetes Mellitus (DM) or fasting blood glucose level &gt; the upper
             normal limit.

          -  Risk of transmitting human immuno-deficiency virus (HIV) or hepatitis B via blood or
             other body fluids, as judged by the investigator.

          -  ECG results considered to be clinically significant as determined by the investigator.

          -  Conditions that could affect absorption and metabolism of study medication.

          -  Patients who in the investigators opinion will require systematic psychotherapy (other
             than supportive psychotherapy) during the study period.

          -  Participation in another clinical study or compassionate use programme within 28 days
             prior to randomisation, or longer if locally required.

          -  Involvement in the planning and conduct of the study (applies to all AstraZeneca or
             staff at the investigational site).

          -  Previous enrolment or randomisation of treatment in the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Hongyan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University 6th hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xijing</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>June 24, 2010</results_first_submitted>
  <results_first_submitted_qc>June 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2012</results_first_posted>
  <last_update_submitted>June 11, 2012</last_update_submitted>
  <last_update_submitted_qc>June 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Mania</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Quetiapine Fumarate</keyword>
  <keyword>Lithium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine Fumarate Used as Mono-Therapy</title>
          <description>Quetiapine Fumarate 600 to 800 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
          <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mismatch Include/Exclude Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Concomitant Medicine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intolerance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No reason was provided</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine Fumarate Used as Mono-Therapy</title>
          <description>Quetiapine Fumarate 600 to 800 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
          <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="189"/>
            <count group_id="B3" value="376"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="12.16"/>
                    <measurement group_id="B2" value="32.43" spread="11.14"/>
                    <measurement group_id="B3" value="33.36" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28)</title>
        <description>The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28)</title>
          <description>The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).</description>
          <population>Per Protocol Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.7" spread="13.7"/>
                    <measurement group_id="O2" value="-26.1" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinical Global Impressions for Bipolar Disorder Severity of Illness (CGI-BP-S) Score to Each Assessment (Day 28)</title>
        <description>The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinical Global Impressions for Bipolar Disorder Severity of Illness (CGI-BP-S) Score to Each Assessment (Day 28)</title>
          <description>The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="0.115"/>
                    <measurement group_id="O2" value="-0.17" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score to Each Assessment (Day 28)</title>
        <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score to Each Assessment (Day 28)</title>
          <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.12" spread="0.285"/>
                    <measurement group_id="O2" value="-16.44" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Each Assessment(Day 28)</title>
        <description>The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms. The MADRS total score is the sum of all 10 individual-item scores and ranges from 0 to 60.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Each Assessment(Day 28)</title>
          <description>The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms. The MADRS total score is the sum of all 10 individual-item scores and ranges from 0 to 60.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="0.181"/>
                    <measurement group_id="O2" value="-3.02" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Young Mania Rating Scale (YMRS) Item 4 Score to Each Assessment</title>
        <description>The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Young Mania Rating Scale (YMRS) Item 4 Score to Each Assessment</title>
          <description>The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.2"/>
                    <measurement group_id="O2" value="-2.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (Number of Patients With Clinically Response)</title>
        <description>The number of patients with clinically response (defined as ≥50% reduction in the YMRS total score from baseline to Day 28) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.</description>
        <time_frame>From Baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Number of Patients With Clinically Response)</title>
          <description>The number of patients with clinically response (defined as ≥50% reduction in the YMRS total score from baseline to Day 28) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Rate (Number of Patients With Clinically Significant Remission)</title>
        <description>The number of patients with clinically significant remission (defined as YMRS total score ≤12) at Day 28 was calculated.
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania. Total score ≤12 indicates remission.</description>
        <time_frame>From Baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Rate (Number of Patients With Clinically Significant Remission)</title>
          <description>The number of patients with clinically significant remission (defined as YMRS total score ≤12) at Day 28 was calculated.
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania. Total score ≤12 indicates remission.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment of Agitation (Change From Baseline in the PANSS Activation Subscale Score to Day 28)</title>
        <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment of Agitation (Change From Baseline in the PANSS Activation Subscale Score to Day 28)</title>
          <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="4.5"/>
                    <measurement group_id="O2" value="-5.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment of Aggression Risk (Change From Baseline in the PANSS Supplement Aggression Risk Subscale Score to Day 28)</title>
        <description>The PANSS Supplemental Aggression Risk subscale score is the sum of 3 standard PANSS items – Excitement, Hostility and Depression – and 3 supplemental PANSS items related to anger – Anger, Difficulty in Delaying Gratification and Affective Lability and ranges from 6 to 42, where 6 is the &quot;best&quot; and 42 the &quot;worst&quot; score for the combined scale.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate Used as Mono-Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
            <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment of Aggression Risk (Change From Baseline in the PANSS Supplement Aggression Risk Subscale Score to Day 28)</title>
          <description>The PANSS Supplemental Aggression Risk subscale score is the sum of 3 standard PANSS items – Excitement, Hostility and Depression – and 3 supplemental PANSS items related to anger – Anger, Difficulty in Delaying Gratification and Affective Lability and ranges from 6 to 42, where 6 is the &quot;best&quot; and 42 the &quot;worst&quot; score for the combined scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.1"/>
                    <measurement group_id="O2" value="-7.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine Fumarate Used as Mono-Therapy</title>
          <description>Quetiapine Fumarate 600 to 800 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Quetiapine Fumarate Used as Adjunct Therapy</title>
          <description>Quetiapine Fumarate 600 to 800 mg/day + lithium 500 mg to 2000 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Extrapyramidal Symptom</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

